Market Intelligence, Clinical Progress, and High-Purity Reagents for Wilson Disease & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATP7B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ATP7B N-Terminal Copper Binding Domain (MBS1-6) High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, HEK293 Expressed (Native Glycosylation). |
View ATP7B Products |
| Mutant Antigen Panel | ATP7B Mutant Recombinant Proteins (e.g., H1069Q, R778L) High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. |
View ATP7B Products |
| Gene Delivery | ATP7B Full-Length Lentivirus Premade Particles EF1α/CMV promoter, Puromycin selection marker, for stable cell line generation preserving membrane topology. |
View ATP7B Products |
| Benchmark Ab | Anti-ATP7B (Research Grade Reference) Recombinant rabbit monoclonal, Sequence Verified, suitable for Western Blot and Immunofluorescence. |
View ATP7B Products |
| Validator | ATP7B siRNA Set Three unique target-specific sequences for knockdown verification and specificity controls. |
View ATP7B Products |
| Related Target: ATP7A | ATP7A (Menkes Disease Protein) Homologous copper transporter for cross-reactivity screening (70% sequence homology). |
View ATP7A Products |
| Related Target: SLC31A1 | SLC31A1 (CTR1) Copper importer, synergistic pathway partner for combination therapy studies. |
View SLC31A1 Products |
| Related Target: ATOX1 | ATOX1 Intracellular copper chaperone; interacts directly with ATP7B. |
View ATOX1 Products |
| Related Target: COMMD1 | COMMD1 Regulates ATP7B degradation and intracellular trafficking. |
View COMMD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Topology (8 TMDs) | Lentivirus-mediated stable expression in HEK293 (Endotoxin <1EU/ug, Native glycosylation, correct folding) |
| Copper Transport Activity Measurement | Compatible with stable cell lines for radioisotope (⁶⁴Cu) or fluorescent probe (Rhodanine-based) uptake assays |
| ATP7A/ATP7B Selectivity Screening | Human/Mouse/Rat ATP7A & ATP7B ortholog proteins available (>95% purity, Sequence Verified by Mass Spec) |
| Gene Therapy Transduction Efficiency | High-titer lentivirus (>1x10⁸ TU/ml) with GFP reporter option for transduction validation |
| Wilson Disease Mutation Spectrum Coverage | Sequence-Verified Mutant Recombinant Proteins (H1069Q, R778L) with >95% purity for pharmacological chaperone selectivity screening |
| Cross-Species Translational Evaluation | Human / Mouse / Cynomolgus ortholog proteins available with >95% purity for preclinical antibody or chaperone validation |
Live ATP7B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ATP7B therapeutics is intensifying, with major players shifting focus from traditional chelation therapy to genetic modalities. As first-generation small molecules (Trientine, Tetrathiomolybdate) face compliance and toxicity challenges, the next wave of R&D targets gene replacement and mRNA therapies. Wilson Disease represents the primary indication, though emerging oncology applications targeting copper-dependent angiogenesis are expanding the addressable market. The critical bottleneck remains functional validation—accurate assessment of copper export activity requires cell models preserving the complex 8-transmembrane topology of ATP7B, necessitating high-fidelity reagents for stable cell line construction.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Voyager (VTX-801), Ultragenyx (UX701), AstraZeneca, Vivet Therapeutics | Wilson Disease | Functional restoration assay (Copper export), requires high-fidelity ATP7B stable cell lines (Lentivirus-based) |
| Small Molecule Chelators | Trientine, Penicillamine, ALXN1840 (bis-choline tetrathiomolybdate) | Wilson Disease, Solid Tumors | Cytotoxicity secondary to copper depletion; ATP7B expression level assays (Western/IHC controls needed) |
| mRNA Therapy | Moderna, Ethris | Wilson Disease | Transient expression validation, translational efficiency assays (Need high-purity ATP7B protein standards) |
| Pharmacological Chaperone | Academic / Biotech Consortia | Wilson Disease (Misfolding Mutants) | Mutant vs. WT binding assay needs high-purity, sequence-verified mutant recombinant proteins |
| Small Molecule Inhibitor | Oncology Biotechs | Platinum-Resistant Solid Tumors | Copper-efflux / Platinum sequestration assay requires ATP7B-expressing stable cell lines and homolog-selective counter-screens (ATP7A) |
Molecular Differentiation & Assay Strategy
ATP7B is a complex 8-transmembrane P-type ATPase responsible for hepatic copper transport and excretion. Key differentiation challenges include:
- Structural Complexity: 8 TMDs, 6 N-terminal metal binding sites (MBS), 1 ATP binding domain (TGD), 1 phosphatase domain (ACT).
- Dynamic Transport Mechanism: Copper binding triggers conformational changes (E1/E2 state transitions) for copper translocation from cytosol to Golgi/bile.
- Mutation Spectrum: Common mutations like H1069Q (misfolding, ER retention) and R778L (Asian hotspot) require specific rescue strategies.
TarMart addresses these with a "Cell-Based First" strategy:
- Core Product: Full-length ATP7B lentivirus particles (>1x10⁸ TU/ml, endotoxin <1EU/ug) for functional cell line generation.
- Auxiliary Validation: Recombinant proteins for soluble domains (MBS1-6, TGD) for binding kinetics studies.
- Control System: ATP7A homolog (off-target control) + ATP7B siRNA (loss-of-function control) for "specificity triangle validation".